Regeneron Ireland Designated Activity Company
Summary
Regeneron Ireland Designated Activity Company was set up on Friday the 2nd of November 2012. Their current partial address is Dublin, and the company status is Normal. The company's current directors have been the director of 3 other Irish companies between them. Regeneron Ireland Designated Activity Company has 1 shareholder. This Irish company shares its Eircode with at least 3 other companies.
Credit Score
- Latest Credit Movement:
- Date of Last Movement:05/12/2024
- Latest Accounts Filed:21/11/2024
- Report Based On Accounts:31/12/2023
- Next Set of Accounts Due:30/09/2025
- Overdue:No
Credit Report
- Credit Report & Financials
- Company Printout Report
- Directors & Owners Report
- Bad Debt Judgments Report
- Mortgages Report
€9
Company Vitals
- Company Name:Regeneron Ireland Designated Activity Company
- Time in Business:12 Years
- Company Number:519550
- Company Size:Large Company
- Current Status:NORMAL
- Principal Activity:[24.42] Manufacture of Pharmaceutical Preparations
- May Trade As:
- Registered Address:One Warrington Place,
Dublin 2, Dublin
D02 HH27
€3
Directors
Purchase either the Standard Company Report or a Credit Report to view details on the directors of this company.
Judgments
Discover poor payment histories of any company by searching our Judgment Database, for court actions brought against a company for non-payment of a debt. Plus get free Judgment monitoring alerts on this company for the next 12 months. Judgments are available as part of the Credit Report.
Documents
| Document | Pages | Effective | Received | Buy |
|---|---|---|---|---|
| Form B1C - Annual Return General | 5 | 30/09/2024 | 21/11/2024 | |
| FINANCIAL STATEMENT | 39 | 30/09/2024 | 21/11/2024 | |
| FINANCIAL STATEMENT | 38 | 30/09/2023 | 20/11/2023 | |
| Form B1C - Annual Return General | 5 | 30/09/2023 | 20/11/2023 | |
| FINANCIAL STATEMENT | 37 | 30/09/2022 | 03/10/2022 | |
| Constitution | 54 | 07/03/2019 | 25/03/2019 | |
| Migrated Certificate | 1 | 02/11/2012 | 18/10/2012 |